Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1984952 | The International Journal of Biochemistry & Cell Biology | 2008 | 13 Pages |
Abstract
The important role of matrix metalloproteinases (MMPs) in the process of carcinogenesis is well established. However, despite very promising activity in a plethora of preclinical models, MMP inhibitors (MMPIs) failed to demonstrate a statistically significant survival advantage in advanced stage clinical trials in most human malignancies. Herein, we review the implication of MMPs in carcinogenesis, outline the pharmacology and current status of various MMPIs as anticancer agents and discuss the etiologies for the discrepancy between their preclinical and clinical evaluation. Finally, strategies for effective incorporation of MMPIs in current anticancer therapies are proposed.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Panagiotis A. Konstantinopoulos, Michalis V. Karamouzis, Athanasios G. Papatsoris, Athanasios G. Papavassiliou,